Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma

Maria Apellaniz-Ruiz; Meta H. Diekstra; Juan M. Roldan; Epie Boven; Daniel Castellano; Hans Gelderblom; Ron H. J. Mathijssen; Jesse J. Swen; Stefan Bohringer; Jesus Garcia-Donas; Brian I. Rini; Henk-Jan Guchelaar; Cristina Rodriguez-Antona

doi:10.1097/FPC.0000000000000280

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma

Maria Apellaniz-Ruiz, Meta H. Diekstra, Juan M. Roldan, Epie Boven, Daniel Castellano, Hans Gelderblom, Ron H. J. Mathijssen, Jesse J. Swen, Stefan Bohringer, Jesus Garcia-Donas, Brian I. Rini, Henk-Jan Guchelaar, Cristina Rodriguez-Antona^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	227-231
Number of pages	5
Journal	Pharmacogenetics and Genomics
Volume	27
Issue number	6
DOIs	https://doi.org/10.1097/FPC.0000000000000280
Publication status	Published - Jun 2017

Keywords

advanced renal cell carcinoma
KDR
polymorphism
sunitinib
vascular endothelial growth factor receptor 2
SINGLE-NUCLEOTIDE POLYMORPHISMS
1ST-LINE SUNITINIB
INDUCED TOXICITY
MARKERS
THERAPY
VEGFR2
IDENTIFICATION
HYPERTENSION
ASSOCIATION
PAZOPANIB

Access to Document

10.1097/FPC.0000000000000280

Cite this

Apellaniz-Ruiz, M., Diekstra, M. H., Roldan, J. M., Boven, E., Castellano, D., Gelderblom, H., Mathijssen, R. H. J., Swen, J. J., Bohringer, S., Garcia-Donas, J., Rini, B. I., Guchelaar, H-J., & Rodriguez-Antona, C. (2017). Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenetics and Genomics, 27(6), 227-231. https://doi.org/10.1097/FPC.0000000000000280

Apellaniz-Ruiz, Maria ; Diekstra, Meta H. ; Roldan, Juan M. ; Boven, Epie ; Castellano, Daniel ; Gelderblom, Hans ; Mathijssen, Ron H. J. ; Swen, Jesse J. ; Bohringer, Stefan ; Garcia-Donas, Jesus ; Rini, Brian I. ; Guchelaar, Henk-Jan ; Rodriguez-Antona, Cristina. / Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. In: Pharmacogenetics and Genomics. 2017 ; Vol. 27, No. 6. pp. 227-231.

@article{6d682ef033594592a4eb09957770ad58,

title = "Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma",

keywords = "advanced renal cell carcinoma, KDR, polymorphism, sunitinib, vascular endothelial growth factor receptor 2, SINGLE-NUCLEOTIDE POLYMORPHISMS, 1ST-LINE SUNITINIB, INDUCED TOXICITY, MARKERS, THERAPY, VEGFR2, IDENTIFICATION, HYPERTENSION, ASSOCIATION, PAZOPANIB",

author = "Maria Apellaniz-Ruiz and Diekstra, {Meta H.} and Roldan, {Juan M.} and Epie Boven and Daniel Castellano and Hans Gelderblom and Mathijssen, {Ron H. J.} and Swen, {Jesse J.} and Stefan Bohringer and Jesus Garcia-Donas and Rini, {Brian I.} and Henk-Jan Guchelaar and Cristina Rodriguez-Antona",

year = "2017",

month = jun,

doi = "10.1097/FPC.0000000000000280",

language = "English",

volume = "27",

pages = "227--231",

journal = "Pharmacogenetics and Genomics",

issn = "1744-6872",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "6",

}

Apellaniz-Ruiz, M, Diekstra, MH, Roldan, JM, Boven, E, Castellano, D, Gelderblom, H, Mathijssen, RHJ, Swen, JJ, Bohringer, S, Garcia-Donas, J, Rini, BI, Guchelaar, H-J & Rodriguez-Antona, C 2017, 'Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma', Pharmacogenetics and Genomics, vol. 27, no. 6, pp. 227-231. https://doi.org/10.1097/FPC.0000000000000280

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. / Apellaniz-Ruiz, Maria; Diekstra, Meta H.; Roldan, Juan M.; Boven, Epie; Castellano, Daniel; Gelderblom, Hans; Mathijssen, Ron H. J.; Swen, Jesse J.; Bohringer, Stefan; Garcia-Donas, Jesus; Rini, Brian I.; Guchelaar, Henk-Jan; Rodriguez-Antona, Cristina.

In: Pharmacogenetics and Genomics, Vol. 27, No. 6, 06.2017, p. 227-231.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma

AU - Apellaniz-Ruiz, Maria

AU - Diekstra, Meta H.

AU - Roldan, Juan M.

AU - Boven, Epie

AU - Castellano, Daniel

AU - Gelderblom, Hans

AU - Mathijssen, Ron H. J.

AU - Swen, Jesse J.

AU - Bohringer, Stefan

AU - Garcia-Donas, Jesus

AU - Rini, Brian I.

AU - Guchelaar, Henk-Jan

AU - Rodriguez-Antona, Cristina

PY - 2017/6

Y1 - 2017/6

KW - advanced renal cell carcinoma

KW - KDR

KW - polymorphism

KW - sunitinib

KW - vascular endothelial growth factor receptor 2

KW - SINGLE-NUCLEOTIDE POLYMORPHISMS

KW - 1ST-LINE SUNITINIB

KW - INDUCED TOXICITY

KW - MARKERS

KW - THERAPY

KW - VEGFR2

KW - IDENTIFICATION

KW - HYPERTENSION

KW - ASSOCIATION

KW - PAZOPANIB

U2 - 10.1097/FPC.0000000000000280

DO - 10.1097/FPC.0000000000000280

M3 - Article

VL - 27

SP - 227

EP - 231

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 6

ER -